Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 4, 2004, Pages 495-498

  Tang, Zhao You ^a   Zhou, Xin Da ^a   Ma, Zeng Chen ^a   Wu, Zhi Quan ^a   Fan, Jia ^a   Qin, Lun Xiu ^a   Yu, Yao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cytoreduction; Downstaging; Hepatocellular carcinoma; Multimodality treatment; Resection

Indexed keywords

CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; AGED; CALCULATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HEPATIC ARTERY LIGATION; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DRUG THERAPY; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIGATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOIMMUNOTHERAPY; RADIOTHERAPY; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 9444233294     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001;91:1479-1486.
2. Reynolds M, Douglass EC, Finegold M, Cantor A, Glicksman A. Chemotherapy can convert unresectable hepatoblastoma. J Pediatr Surg 1992;27:1080-1083.
3. Sitzmann JV, Order SE, Klein JL, Leichner PK, Fishman EK, Smith GW. Conversion by new treatment modalities of unresectable to resectable hepatocellular carcinoma. J Clin Oncol 1987;5:1566-1573.
4. Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993;217:149-154.
5. Tang ZY, Yu YQ. Long-term survival of hepatocellular carcinoma with reference to the role of early resection, multioperation and multimodality treatment. Gann Monogr Cancer Res 1986;31:185-190.
6. Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Liu KD, et al. Cytoreduction and sequential resection: A hope for unresectable primary liver cancer. J Surg Oncol 1991;47:27-31.
7. Tang ZY, Yu YQ, Zhou XD, Ma ZC, Yang BH, Lin ZY, et al. Treatment of unresectable primary liver cancer: with reference to cytoreduction and sequential resection. World J Surg 1995;19:47-52.
8. Tang ZY, Yu YQ, Zhou XD, Ma ZC, Lu JZ, Lin ZY, et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma-evaluation with analysis of 72 patients. World J Surg 1995;19:784-789.
9. Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY, Mack P. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993;71:62-65.
10. Fan J, Tang ZY, Yu YQ, Wu ZQ, Ma ZC, Zhou XD, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998;15:674-678.
11. Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000;7:490-495.
12. Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001;233:236-241.
13. Hoffman AL, Wu SS, Obaid AK, French SW, Lois J, McMonigle M, et al. Histologic evaluation and treatment outcome after sequential radiofrequency ablation and hepatic resection for primary and metastatic tumors. Am Surg 2002;68:1038-1043.
14. Zhou XD, Tang ZY, Yu YQ, Ma ZC, Xu DB, Bao YM, et al. Hepatic artery ligation and infusion chemotherapy for unresectable primary liver cancer. Chin Med J 1991;104:846-850.
15. Tang ZY, Liu KD, Bao YM, Lu JZ, Yu YQ, Ma ZC, et al. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer 1990;65:211-215.
16. Tang ZY, Liu KD, Fan Z, Lu JZ, Zhang YJ, Bao YM, et al. A decade's studies on the immunotargeting therapy of hepatocellular carcinoma. Antibody Immunoconj Radiophar 1993;6: 155-165.
17. Tang ZY, Zeng ZC . Liu KD, Yu YQ, Lu JZ, Xie H. Intrahepatic arterial I-131 anti hepatocellular carcinoma (HCC) monoclonal antibody combined with hepatic artery ligation for treatment of unresectable HCC. Antibody Immunoconj Radiophar 1993;6:167-175.
18. Lu JZ, Li BX, Liu KD, Yu YQ, Tang ZY. Alternating chemotherapy and fractionated radiotherapy as a modality for the treatment of primary liver cancer. Chin J Cancer Res 1994;6: 69-73.
19. Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002;131:433-442.
20. 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 2001; 16:333-338.
21. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226:688-701.
22. Huang J, He X, Lin X, Zhang C, Li J. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chin Med J 2000;113:446-448.
23. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421-427.
24. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000;32:43-48.